Results 271 to 280 of about 8,093,285 (389)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Patient reported outcomes that matter to individuals with (genetic) intellectual disabilities: a qualitative study. [PDF]

open access: yesJ Neurodev Disord
van Silfhout NY   +4 more
europepmc   +1 more source

PMD18 REAL-LIFE PATIENT REPORTED OUTCOMES: DATA MINING OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINS

open access: bronze, 2004
MW Reynolds   +4 more
openalex   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

open access: yesMolecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy